Cresset Asset Management LLC Sells 1,035 Shares of BioNTech SE Sponsored ADR $BNTX

Cresset Asset Management LLC lessened its stake in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 17.8% in the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 4,764 shares of the company’s stock after selling 1,035 shares during the period. Cresset Asset Management LLC’s holdings in BioNTech were worth $434,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of BNTX. Raymond James Financial Inc. purchased a new position in shares of BioNTech in the fourth quarter valued at about $584,000. CANADA LIFE ASSURANCE Co lifted its position in shares of BioNTech by 63.5% in the fourth quarter. CANADA LIFE ASSURANCE Co now owns 7,791 shares of the company’s stock valued at $887,000 after acquiring an additional 3,025 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in shares of BioNTech by 61.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,881 shares of the company’s stock valued at $214,000 after acquiring an additional 713 shares in the last quarter. T. Rowe Price Investment Management Inc. purchased a new position in shares of BioNTech in the fourth quarter valued at about $6,078,000. Finally, Banco Bilbao Vizcaya Argentaria S.A. purchased a new position in shares of BioNTech in the fourth quarter valued at about $786,000. Institutional investors own 15.52% of the company’s stock.

BioNTech Price Performance

NASDAQ:BNTX opened at $110.88 on Monday. The company has a current ratio of 8.61, a quick ratio of 8.48 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $26.66 billion, a P/E ratio of -69.30 and a beta of 1.23. BioNTech SE Sponsored ADR has a 12 month low of $81.20 and a 12 month high of $131.49. The business’s 50-day moving average is $109.90 and its 200 day moving average is $105.38.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings data on Monday, August 4th. The company reported ($1.60) earnings per share for the quarter, missing the consensus estimate of ($1.41) by ($0.19). BioNTech had a negative return on equity of 1.84% and a negative net margin of 12.20%.The company had revenue of $306.46 million for the quarter, compared to the consensus estimate of $161.26 million. During the same period in the previous year, the firm earned ($3.36) earnings per share. The company’s revenue was up 102.6% compared to the same quarter last year. BioNTech has set its FY 2025 guidance at EPS. On average, equities research analysts forecast that BioNTech SE Sponsored ADR will post -3.88 earnings per share for the current fiscal year.

Analysts Set New Price Targets

BNTX has been the topic of several research analyst reports. Citigroup restated a “buy” rating and issued a $140.00 price objective (down from $145.00) on shares of BioNTech in a research report on Tuesday, May 6th. The Goldman Sachs Group initiated coverage on BioNTech in a research report on Thursday, May 29th. They issued a “neutral” rating and a $110.00 price objective on the stock. Leerink Partners set a $112.00 price objective on BioNTech in a research report on Monday, June 2nd. Morgan Stanley boosted their price objective on BioNTech from $132.00 to $133.00 and gave the company an “overweight” rating in a research report on Thursday, July 10th. Finally, Truist Financial reiterated a “buy” rating and issued a $155.00 target price (up from $151.00) on shares of BioNTech in a research report on Tuesday, June 3rd. Thirteen investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $135.80.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.